基于衰减估计的心肌细胞外容积在非心电门控全身CT中作为化疗所致心脏毒性早期生物标志物的初步研究
回顾性纳入89例接受化疗的癌症患者(高心脏毒性风险组58例、低风险组31例),在化疗前和首周期化疗后行非心电门控全身CT,用自建软件基于衰减估计心肌细胞外容积(ABE-ECV)并计算动脉期心肌λ。高风险组室间隔ABE-ECV从32%(31-35%)升至37%(35-39%)(p=0.0002),侧壁从30%(27-31)升至32%(29-34)(p=0.028);低风险组室间隔(p=0.16)和侧壁(p=0.93)无显著变化。
要点
- 非心电门控全身CT可用于估计心肌ABE-ECV,高心脏毒性风险化疗后室间隔和侧壁ABE-ECV升高。
- 高风险组动脉期心肌λ在化疗后降低者占31%,低风险组占10%(p=0.036)。
核心结论
- 初步研究表明,在接受化疗的癌症分期患者中,可在非心电门控全身CT上估计ECV;潜在心脏毒性化疗可能与ABE-ECV和动脉心肌λ的改变相关。
研究设计与样本
- 回顾性纳入连续接受化疗且具有高(高风险组)或低(低风险组)心脏毒性风险的患者,共89例(平均年龄63±14岁),高风险组58例、低风险组31例;患者在癌症分期前(CT-I)和首周期化疗后(CT-II)行全身CT,分析平扫、动脉期和延迟期图像,用自建软件生成ABE-ECV图并计算动脉心肌λ。
诊断标准与关键数值
- ABE-ECV由平扫图像感兴趣区与延迟期图像逐像素分析联合生成;动脉心肌λ=心肌密度增加量/血液密度增加量(动脉期较基线)。
- 高风险组室间隔ABE-ECV从32%(31-35%)升至37%(35-39%)(p=0.0002),侧壁从30%(27-31)升至32%(29-34)(p=0.028)。
- 低风险组室间隔ABE-ECV变化无统计学显著差异(p=0.16),左室侧壁ABE-ECV变化无统计学显著差异(p=0.93)。
- CT-II动脉心肌λ较CT-I降低者在高风险组占31%,低风险组占10%(p=0.036)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: To evaluate whether myocardial extracellular volume (ECV) could be estimated from whole-body CT examinations without electrocardiographic gating in cancer patients before and after the chemotherapy, with the goal to detect early-stage myocardial alterations heralding chemotherapy-induced cardiotoxicity.
MATERIAL AND METHODS: Consecutive patients receiving chemotherapy with a high (High-risk group) or low (Low-risk group) risk of cardiotoxicity were retrospectively enrolled. Patients underwent a whole-body CT examination for cancer staging before (CT-I) and after the first chemotherapy cycle (CT-II). Precontrast, arterial phase, and late post-contrast CT-I and CT-II images were analysed using in-house software. Myocardial Attenuation-based estimation of ECV (ABE-ECV) maps were generated from the combined analysis of regions of interest in precontrast images and a pixel-wise analysis of late post-contrast images, whereas the increase of myocardial and blood densities in arterial phase from basal values were compared to calculate arterial myocardial λ (arterial increase of myocardial density/increase of blood density).
RESULTS: The population included 89 patients (mean age 63 ± 14 years): 58 High-Risk and 31 Low-Risk. High-risk patients showed a significant increase of ABE-ECV of the interventricular septum, from 32% (31-35%) to 37% (35-39%) (p = 0.0002) and lateral wall, from 30% (27-31) to 32% (29-34) (p = 0.028). In contrast, Low-risk patients showed no significant variation of septal (p = 0.16) and LV lateral wall ABE-ECV (p = 0.93). Arterial myocardial λ at CT-II was reduced compared to CT-I in 31% of High-risk patients vs 10% of Low-risk patients (p = 0.036).
CONCLUSION: This preliminary study demonstrated that ECV can be estimated in ECG-ungated whole-body CT examinations for cancer staging in patients undergoing chemotherapy. Potentially cardiotoxic chemotherapy can be associated with alterations of ABE-ECV and arterial myocardial λ.
引用
- Aquaro GD, Faggioni L, Francischello R, et al. Attenuation-based estimation of myocardial extracellular volume from ECG-ungated whole-body CT examinations as an early biomarker of chemotherapy-induced cardiotoxicity: preliminary findings. Radiol Med. 2025. PMID: 41252121. doi:10.1007/s11547-025-02148-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。